Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Q1 2026 Earnings Presentation
34 slides from Hansa Biopharma Ab's earnings presentation, Apr 23, 2026
Slide 1: Q1 2026 Report Conference Call
® Q1 2026 Report Conference Call 23rd of April 2026
Slide 2: Forward-looking statements
® Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will o
Slide 3: Q1 2026 Conference Call: Agenda
Q1 2026 Conference Call: Agenda ® 23rd of April, 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Pipeline Update Richard Philipson Chief Medical Officer Financial Results Evan Ballantyne Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO © 2
Slide 4: Key Achievements in Q1 2026
® Key Achievements in Q1 2026 Business Overview Commercial & Pipeline Update Quarters remain highly variable, impact on Q1 from reorganization as expected: Q1 FDA review ongoing revenues: 34.6 MSEK vs 66.3 MSEK Q1 25 Constructive interactions. Ongoing Q&A process Capital raise: $30M in convertible n
Slide 5: Key European Initiative
Key European Initiative ® Actions to Date Focus and Key Events New leadership Company-wide Integrated medical affairs and commercial • Upcoming topline data from PAES Updates organization under one leader • Real world data from France KOLs to be published ATC acceptance of oral presentation of
Slide 6: General Outlook 2026
General Outlook 2026 ® One year in – structural changes across the business implemented. Substantial improvements achieved with regards to financial stability, runway, pipeline strategy, internal expertise and experience. Positive outlook for the year reflecting several key data related mileston
Slide 7: Q1 2026 Conference Call: Agenda
Q1 2026 Conference Call: Agenda ® 23rd of April, 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Pipeline Update Richard Philipson Chief Medical Officer Financial Results Evan Ballantyne Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO © 2
Slide 8: Idefirix has unique position in Europe: large market with no competition
Idefirix has unique position in Europe: large market with no ® competition OPPORTUNITY No competition – there are no approved desensitization approaches apart from Idefirix 7,000-11,000 Highly Sensitized patients wait 7-12 years for a transplant(1) Highly sensitized patients are less likely to
Slide 9: Q1 Performance impacted by organizational changes in European business
Q1 Performance impacted by organizational changes in ® European business Performance Operational activities German KOLs submitted new consensus recommendations for publication; already discussed in webinar with large German transplant centers 33.9M SEK product sales KOL expert meetings and webinars
Slide 10: The US Market Represents a Significant Opportunity
The US Market Represents a Significant Opportunity ® US Transplant Waitlist ~ 15% of patients are highly sensitized (cPRA > 80%) The US represents a significant market opportunity ~100,000 ~15k highly sensitized on the wait list patients with cPRA >80% ~45,000 new additions to the wait list each yea
Slide 11: Recent US Market Research Studies Confirm Commercial Opportunity
Recent US Market Research Studies Confirm Commercial ® Opportunity High unmet need: current off-label treatments are not seen as great options for patients Multiple stakeholders involved in transplants: HLA Lab Director plays a critical role in management of antigen profile and delisting protoco
Slide 12: U.S. launch preparations continuing with focus on site of care strategy and market access
U.S. launch preparations continuing with focus on site of care strategy ® and market access 200 transplant centers Pricing and Reimbursement Pre-launch activities 100 ~80% Majority of Transplants are paid by Organizational Build Centers of transplant volume Medicare Expanding field access and medica
Slide 13: Q1 2026 Conference Call: Agenda
® Q1 2026 Conference Call: Agenda 23rd of April, 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Pipeline Update Richard Philipson Chief Medical Officer Financial Results Evan Ballantyne Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO © 2
Slide 14: Study 20-HMedIdeS-19 (PAES)
® Study 20-HMedIdeS-19 (PAES) A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase treatment, including non- comparative registry and concurrent reference coho
Slide 15: Objectives
® Objectives Primary To determine the 1-year graft failure-free survival in highly sensitized kidney transplant patients, pre-treated with imlifidase to turn a positive crossmatch against a deceased donor into a negative crossmatch Secondary To evaluate, up to 1 year after transplantation: Renal f
Slide 16: Study Design
® Study Design Imlifidase treatment group Identify highly sensitized patients with the highest unmet medical need based on the local allocation system Screening Imlifidase-Tx Pre-screening Organ offer Inclusion XM-conversion Positive XM (pos to neg) Delisting of unacceptable antigen(s) 12 months Non
Slide 17: Treatment Schema – Imlifidase Treatment
® Treatment Schema – Imlifidase Treatment All patients premedicated with intravenous methylprednisolone (250 mg) and an antihistamine (oral loratadine 10 mg or equivalent) 2nd dose of imlifidase can be given within 24 hours, if required © 2026, Hansa Biopharma AB 17
Slide 18: Study Conduct and Status
® Study Conduct and Status 3 sites 2 sites 1 site Study started May 2022 (FPFV) 2 sites 2 sites 11 countries (10 EU and UK) 1 site 22 sites 3 sites 1 site Database lock expected in May 1 site 4 sites 2 sites © 2026, Hansa Biopharma AB Confidential Information 18
Slide 19: HNSA-5487
® HNSA-5487 HSNA-5487 in Guillain-Barré Syndrome © 2026, Hansa Biopharma AB
Slide 20: Guillain-Barré Syndrome Overview
® Guillain-Barré Syndrome Overview Guillain-Barré Syndrome IgG is a key driver of inflammatory attacks on peripheral nerves and has a rare, acute, paralyzing, inflammatory been clinically linked to the severity and progression of the disease. disease of the peripheral nervous system caused by the im
Slide 21: Overview of Imlifidase Phase 2 Study in GBS
® Overview of Imlifidase Phase 2 Study in GBS Visit 10 Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9 (phone call) Day 3-7 IVIg End of treatment study Screening Imlifidase Assessments 0.25 mg/kg Day 1-2 Day 3-7 Day 8 Day 15 Day 29 Day 57 Day 92 Day 180 Day 360 • 30 patients
Slide 22: Improvement
Mean change in MRC sum score (+/-SEM) over time in patients treated with imlifidase followed by IVIg compared to IGOS cohort ® (naïve comparison) MRC sum scores increase rapidly following imlifidase dosing and continue to increase in the months of follow-up Statistically significanta differences obs
Slide 23: Current Status of HNSA-5487
® Current Status of HNSA-5487 • Phase 1 healthy volunteer study completed • Rapid and robust IgG reduction by more than 95% within a few hours • Significantly reduced ADA response • At least as efficacious as imlifidase in reducing total IgG levels • No tolerability or safety concerns • Design of cl
Slide 24: Q1 2026 Conference Call: Agenda
® Q1 2026 Conference Call: Agenda 23rd of April, 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Pipeline Update Richard Philipson Chief Medical Officer Financial Results Evan Ballantyne Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO © 2
Slide 25: Q1 2026 IDEFIRIX Sales Performance
® Q1 2026 IDEFIRIX Sales Performance Revenue (Q/Q) Product Sales (Q/Q) Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 76.0 66.3 49.1 MSEK 61,1 MSEK Product 34.6 65,7 30.8 Product 61,1 Sales 65,7 Sales 47,8 47,8 33,9 30,1 30,1 33,9 14,9 Contract Revenue* 0,7 1.4 0,7 0,7 Revenue (FY/FY) P
Slide 26: Continued Investments in R&D & Commercialization
® Continued Investments in R&D & Commercialization SG&A Expenses (Q/Q) R&D Expenses (Q/Q) Operating Loss (Q/Q) Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 -76 -91 -88 -102 -106* -64 -57 -93 MSEK -70 MSEK MSEK -74 -125 -96 -155 -148 -143 * - Includes one-
Slide 27: Summary of Cash & Headcount
® Summary of Cash & Headcount Operating Cash Flow (Q/Q) Cash & Cash Equivalents (Q/Q) Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 701 677 MSEK MSEK -99 -112 354 -152 -152 -157 250 252 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Operating Cash Flow (FY/FY) Number of Employees (Q/Q) 2023 2024 2025 Q1'26 -157 Employees 140 MSEK 1
Slide 28: Q1 2026 Conference Call: Agenda
Q1 2026 Conference Call: Agenda ® 23rd of April, 2026 CEO Remarks Renée Aguiar-Lucander CEO Operational Update Maria Törnsén COO, President US Pipeline Update Richard Philipson Chief Medical Officer Financial Results Evan Ballantyne Chief Financial Officer Close and Q&A Renée Aguiar-Lucander CEO © 2
Slide 29: Summary
Summary ® Strong foundation and clear roadmap Robust financial position Value inflection points in Q2 and Q4 Execution focus Experienced team © 2026, Hansa Biopharma AB 29
Slide 30: Hansa Biopharma Capital Markets Day
Hansa Biopharma Capital Markets Day ® Featuring Key European and American Medical Experts Thursday 25th of June, 2026 from 9:00 AM to 12:00 PM EDT • In-Person: The St. Regis Hotel New York, U.S. Location: • Virtual: Live webcast In-Person Sign-up and Webcast Access: More details and full agenda to f
Slide 31: Highly experienced leadership team
Highly experienced leadership team Proven track record delivering growth, approvals, and launches across renal, rare disease, and immunology ® Renée Aguiar-Lucander Maria Törnsén CEO COO, President US 20+ yrs rare disease leader and former investor, took Successfully launched multiple orphan drugs i
Slide 32: Q&A
® Q&A © 2026, Hansa Biopharma AB 32
Slide 33: Hansa Biopharma contacts and key events
® Hansa Biopharma contacts and key events Contacts Upcoming Events 2026 Evan Ballantyne 19 MAY H.C.W. Annual BioConnect Investor Conference, NY Chief Financial Officer Email: ir@hansabiopharma.com 19 MAY LSX Nordic Congress, Copenhagen 20 MAY Investerar-AW med Inderes x InvesteraMera, Stockholm 1 JU
Slide 34: HAN Sar
IZ HAN Sar BIOPHARMA